In benign and malignant vascular tumors, including angiosarcoma, Kaposi’s sarcoma, hemangioendothelioma, and hemangioma, GHR is significantly upregulated in both cytoplasm and nuclei, implying that tumor cells are targets for GH action. Here, GH1 is linked to neoplasm.